Please login to the form below

Not currently logged in


This page shows the latest spondyloarthritis news and features for those working in and with pharma, biotech and healthcare.

UCB supports social network for SpA patients

UCB supports social network for SpA patients

MySpondylitisTeam is launched by MyHealthTeams. UCB has partnered with MyHealthTeams to launch a new social network called MySpondylitisTeam for patients with the chronic and inflammatory arthritis spondyloarthritis (SpA). ... Eric Peacock, co-founder

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Lucid Group make the cut at the PMEAs 2017

    Category: Supporting Patients and Professionals. DUET: Harnessing the Power of Collaboration from Concept to Completion – Improving Patient Care in Spondyloarthritis,  by AbbVie,  with support from Lucid Group.

  • Infographic: Spondyloarthritis

    Overview of spondyloarthritis patient profiles and treatment pathways. Spondyloarthritis is the name for a family of arthritis causing inflammatory rheumatic diseases; including axial spondyloarthritis, psoriatic arthritis and akylosing spondylitis,

  • Research Partnership

    Infographic: Spondyloarthritis. ... Overview of spondyloarthritis patient profiles and treatment pathways.

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...